EcoR1, affiliates report ~9.9% holdings in Eloxx (NASDAQ: ELOX)
Rhea-AI Filing Summary
Eloxx Pharmaceuticals, Inc. Schedule 13G filing shows EcoR1 Capital, LLC, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman reporting shared beneficial ownership of common stock. The filing lists 403,586 shares (EcoR1 and Mr. Nodelman) and 377,635 shares (Qualified Fund), representing 9.9% and 9.3% of the class respectively. The percentages are calculated using 4,036,314 shares outstanding following an offering disclosed in a prospectus filed 06/09/2026. The reporting persons state the holdings were not acquired to change control and disclaim group membership beyond the joint filing.
Positive
- None.
Negative
- None.
Insights
Large passive stakes reported by an institutional investor and related persons.
The filing shows EcoR1 Capital and affiliates hold 403,586 shares (reported as 9.9%) and the Qualified Fund holds 377,635 shares (9.3%), calculated on an outstanding base of 4,036,314 shares as of the prospectus dated 06/09/2026.
These positions are presented as shared voting/dispositive power rather than sole control; the signers disclaim group control and state the stakes were not acquired to change issuer control. Subsequent filings would show any trading activity or changes in percent ownership.
Beneficial ownership near 10% triggers typical disclosure thresholds and ownership limits.
The reporting notes pre-funded warrants and a 9.99% beneficial ownership limitation used in percentage calculations. That qualifier appears to cap exercises or holdings for conversion instruments and is cited verbatim in the cover comments.
Because the filing disclaims intent to influence control and attaches an agreement for joint filing, governance implications are routine disclosure; monitor future filings for any schedule amendments or Form 4s that would indicate active transactions.
Key Figures
Key Terms
Beneficial ownership limitation regulatory
Pre-funded warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.